Interestingly, patients harbouring IDH1R132H mutated tumours have lower levels of genome-wide DNA methylation, an increased gene expression and the worst prognosis compared to patients affected by tumours with other IDH1/2 mutations [72]. The gene discussed is IDH1; the disease is neoplasm.